Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Endo Int'l Plc (ENDP)

Endo Int'l Plc (ENDP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Endo Int'l Plc First Floor Minerva House Simmonscourt Road Ballsbridge Dublin L2 19355 IRL

P: 011-353-1268

Description:

Endo International plc is a global specialty pharmaceutical company, which is focused on branded and generic pharmaceuticals. The four reportable business segments are: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. The Branded Pharmaceuticals segment consists of the company's legacy generics business together with the generic pharmaceuticals products obtained through the September 2015 acquisition of Par Pharmaceutical Holdings, Inc. (Par). The Sterile Injectables segment consists primarily of branded sterile injectable products such as Vasostrict, Adrenalin and Aplisol, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The Generic Pharmaceuticals portfolio includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics.

Key Statistics

Overview:

Market Capitalization, $K 86,451
Shares Outstanding, K 235,114
Annual Sales, $ 2,993 M
Annual Net Income, $ -613,250 K
Last Quarter Sales, $ 652,260 K
Last Quarter Net Income, $ -71,970 K
60-Month Beta 1.12
% of Insider Shareholders 2.70%
% of Institutional Shareholders 80.39%
Float, K 228,766
% Float 97.30%
Short Volume Ratio 0.46

Growth:

1-Year Return -92.48%
3-Year Return -91.08%
5-Year Return -96.71%
5-Year Revenue Growth -25.36%
5-Year Earnings Growth -35.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.66 on 05/05/22
Next Earnings Date 08/04/22
Earnings Per Share ttm 2.95
EPS Growth vs. Prev Qtr -21.43%
EPS Growth vs. Prev Year -9.59%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ENDP Ratios

Ratio
Price/Earnings ttm 0.13
Price/Earnings forward 0.50
Price/Earnings to Growth N/A
Return-on-Equity % -72.22%
Return-on-Assets % 7.82%
Profit Margin % -20.49
Net Margin % 12.13
Debt/Equity N/A
Price/Sales 0.03
Price/Cash Flow 0.08
Price/Book N/A
Book Value/Share -5.58
Interest Coverage -0.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar